

Documents

Vanderick, A.<sup>a</sup> , Colinet, B.<sup>b</sup>

**Absence of cross-toxicity between MET inhibitors in a non-small-cell lung cancer with a MET exon 14 skipping mutation**  
(2024) *Acta Clinica Belgica: International Journal of Clinical and Laboratory Medicine*, 79 (2), pp. 148-151.

**DOI:** 10.1080/17843286.2024.2330137

<sup>a</sup> Pneumology, Université catholique de Louvain (UCL), Brussels, Belgium  
<sup>b</sup> Department of Pneumology, Grand hôpital de Charleroi, Charleroi, Belgium

**Abstract**  
Introduction: Selective tyrosine kinase inhibitors are proven effective in patients with non-small lung cancer (NSCLC) with a MET exon 14 skipping mutation. Case presentation: The patient developed a metastatic lung adenocarcinoma with a MET exon 14 skipping mutation. She was treated with a first 1b MET inhibitor, Capmatinib, but had to stop the drug because of major hepatotoxicity. A few months later, she started Tepotinib, another 1b MET inhibitor with this time, no sign of hepatotoxicity. Discussion: Adverse events are frequent with 1b MET inhibitors. However, there is a wide interpatient variability. Absence of cross-toxicity between Capmatinib and Tepotinib is misunderstood but can be explained by slight differences in pharmacodynamics and pharmacokinetics. Practitioners have to be warned about severe adverse events to stop or change the drug if necessary. Conclusion: This is the first case showing the absence of cross-toxicity between 1b MET inhibitors. © Belgian Society of Internal Medicine and Royal Belgian Society of Laboratory Medicine (2024).

**Author Keywords**  
MET exon 14 skipping mutation; MET inhibitor; toxicity: capmatinib, Tepotinib

**Index Keywords**  
creatinine, durvalumab, erlotinib, pemetrexed, tamoxifen, acrylamide derivative, antineoplastic agent, benzamide derivative, capmatinib, imidazole derivative, MET protein, human, piperidine derivative, protein kinase inhibitor, pyridazine derivative, pyrimidine derivative, scatter factor receptor, tepotinib, triazine derivative; Article, thoracocentesis, transthoracic biopsy, case report, drug therapy, exon, female, genetics, human, lung tumor, middle aged, mutation, non small cell lung cancer; Acrylamides, Antineoplastic Agents, Benzamides, Carcinoma, Non-Small-Cell Lung, Exons, Female, Humans, Imidazoles, Lung Neoplasms, Middle Aged, Mutation, Piperidines, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-met, Pyridazines, Pyrimidines, Triazines

**Correspondence Address**  
Vanderick A.; Pneumology, Avenue Maurice Maeterlinck 6, Belgium; email: ariane.vanderick@gmail.com

**Publisher:** Taylor and Francis Ltd.

**ISSN:** 17843286  
**CODEN:** ACCBA  
**PubMed ID:** 38494868  
**Language of Original Document:** English  
**Abbreviated Source Title:** Acta Clin. Belg. Int. J. Clin. Lab. Med.  
2-s2.0-85188418958  
**Document Type:** Article  
**Publication Stage:** Final  
**Source:** Scopus